Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study

BackgroundIndividuals with bipolar disorder face a significantly elevated suicide risk, and comorbid type 2 diabetes mellitus (T2DM) further complicates their psychiatric and medical outcomes. Sodium–glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated cardiometabolic benefits in T2DM, bu...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Frontiers in Pharmacology
المؤلفون الرئيسيون:	En-Wei Chang, Jing-Yang Huang, Shih-Chang Lo, Chien-Ning Huang, Yi-Sun Yang, Edy Kornelius
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2025-06-01
الموضوعات:	bipolar diabetes SGLT2 DPP4 cohort study
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1601118/full

مواد مشابهة

Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes
حسب: Edy Kornelius, وآخرون
منشور في: (2025-10-01)

Association between bipolar disorder and diabetic ketoacidosis/hyperosmolar hyperglycemic state
حسب: Han-Jung Liu, وآخرون
منشور في: (2025-07-01)

Evaluating the association between gestational diabetes and neonatal hypoglycemia in Taiwan: a retrospective study of 2,149 pregnancies
حسب: Shiang-Hua Chang, وآخرون
منشور في: (2025-09-01)

The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy
حسب: Edy Kornelius, وآخرون
منشور في: (2024-10-01)

Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study
حسب: Yi-Ting Yeh, وآخرون
منشور في: (2025-07-01)

Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study
حسب: Yi-Sun Yang, وآخرون
منشور في: (2024-07-01)

Anxiety disorders in patients with thyroid nodules vs. thyroid cancer: a retrospective cohort study
حسب: Edy Kornelius, وآخرون
منشور في: (2025-04-01)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
حسب: Annamaria Mascolo, وآخرون
منشور في: (2023-11-01)

Correction: Association between bipolar disorder and diabetic ketoacidosis/hyperosmolar hyperglycemic state
حسب: Han-Jung Liu, وآخرون
منشور في: (2025-09-01)

Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
حسب: Makoto Fujiwara, وآخرون
منشور في: (2022-03-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
حسب: Miao X, وآخرون
منشور في: (2025-01-01)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
حسب: Victor Chien-Chia Wu, وآخرون
منشور في: (2022-09-01)

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
حسب: Xiaoyan Liang, وآخرون
منشور في: (2025-01-01)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
حسب: Honghong Zou, وآخرون
منشور في: (2017-05-01)

In Silico Screening and Identification of Antidiabetic Inhibitors Sourced from Phytochemicals of Philippine Plants against Four Protein Targets of Diabetes (PTP1B, DPP-4, SGLT-2, and FBPase)
حسب: Mark Andrian B. Macalalad, وآخرون
منشور في: (2023-07-01)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
حسب: Magdalena Złotek, وآخرون
منشور في: (2023-11-01)

Association of herpes zoster vaccination and cardiovascular risk in patients with diabetes: long-term insights from a retrospective cohort study
حسب: Yu-Hsun Wang, وآخرون
منشور في: (2025-02-01)

The efficacy of pioglitazone for renal protection in diabetic kidney disease
حسب: Chao-Chung Ho, وآخرون
منشور في: (2022-01-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
حسب: Birdie Huang, وآخرون
منشور في: (2025-02-01)

Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based studyResearch in context
حسب: Yoko Narasaki, وآخرون
منشور في: (2024-08-01)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
حسب: Shen L, وآخرون
منشور في: (2021-04-01)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
حسب: Dario Giugliano, وآخرون
منشور في: (2022-03-01)

Staging of suicidality in bipolar disorder: Findings from the FACE-BD cohort (FondaMental Advanced Centers of Expertise for Bipolar Disorders)
حسب: Anna Maria Auxilia, وآخرون
منشور في: (2025-01-01)

Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life
حسب: Ramón Baeza-Trinidad, وآخرون
منشور في: (2023-07-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
حسب: Diego Rivas‐Otero, وآخرون
منشور في: (2025-03-01)

Benefits of SGLT2 inhibitors in arrhythmias
حسب: Jinghan Gao, وآخرون
منشور في: (2022-10-01)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
حسب: Kai-Fan Tsai, وآخرون
منشور في: (2021-07-01)

Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm
حسب: Jianyi Li, وآخرون
منشور في: (2023-08-01)

SGLT-2 inhibitors in chronic peritoneal dialysis patients: a follow-up study
حسب: Jia-Wen Lai, وآخرون
منشور في: (2024-07-01)

SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
حسب: Taimin Luo, وآخرون
منشور في: (2025-07-01)

Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
حسب: Yi-lin Huang, وآخرون
منشور في: (2023-06-01)

The potential anti-arrhythmic effect of SGLT2 inhibitors
حسب: Hong-Yi Duan, وآخرون
منشور في: (2024-07-01)

Are the Newer Antidiabetic Agents Worth the Cost?
حسب: Sudhakar Pemminati, وآخرون
منشور في: (2016-03-01)

Three Levels of Disease Modification with SGLT-2 Inhibitors: Holy Grail in Vasculopathy
حسب: Archit Dhaiya; Rajeev Sharma; Nagendra Bhoopathy; Rajeev Agarwal
منشور في: (2023-07-01)

Sodium-glucose cotransporter 2 Inhibitors and COVID-19 outcomes in type 2 diabetes patients: A population-based cohort study
حسب: Cerina Dubois, وآخرون
منشور في: (2025-07-01)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
حسب: A. A. Volodin, وآخرون
منشور في: (2018-02-01)

The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials
حسب: Mohammad Amin Karimi, وآخرون
منشور في: (2025-06-01)

Age-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation
حسب: Su-Kiat Chua, وآخرون
منشور في: (2025-01-01)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
حسب: Maria Elena Lunati, وآخرون
منشور في: (2022-09-01)

SGLT2-Inhibitors - significant role in Heart Failure treatment
حسب: Karol Wielgus, وآخرون
منشور في: (2024-05-01)